Revenue
2020
2021
2022
2023
2024
2025
GRI Bio, Inc. (GRI)
Price$1.94Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $100,000 |
| Research & development | $6.8M | $3.8M | $3.2M | $242,000 | $5.2M | $3.7M |
| Operating expenses | $12.0M | $8.2M | $11.4M | $2.2M | $9.3M | $4.9M |
| Operating income | −$12.0M | −$8.2M | −$11.4M | −$2.2M | −$9.3M | −$4.8M |
| Operating margin | — | — | — | — | — | −4,788.00% |
| EBITDA | −$12.0M | −$8.2M | −$11.4M | −$2.0M | — | — |
| Net income | −$12.0M | −$8.2M | −$13.0M | −$3.2M | −$9.3M | −$4.8M |
| Net profit margin | — | — | — | — | — | −4,822.00% |
| Basic EPSper basic share | -$121.80 | -$1,545.55 | -$2,275,727.36 | -$2,009,890.18 | -$24,038,848.49 | -$18,113,780.20 |
| Diluted EPSper diluted share | -$121.80 | -$1,545.55 | -$2,275,727.36 | -$2,009,890.18 | -$24,038,848.49 | -$18,113,780.20 |
Owners
Reported shareholders
1.32%of listed shares
HRT FINANCIAL LP28.78K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
HRT FINANCIAL LP | 1.32%28.78K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.98%21.37K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.63%13.87K shares |
CITADEL ADVISORS LLC | 0.61%13.38K shares |
MORGAN STANLEY | 0.40%8.74K shares |
UBS Group AG | 0.23%4.92K shares |
Tower Research Capital LLC (TRC) | 0.11%2.43K shares |
BARCLAYS PLC | <0.01%83 shares |
BlackRock, Inc. | <0.01%7 shares |
DANSKE BANK A/S | <0.01%2 shares |
Caitong International Asset Management Co., Ltd | <0.01%2 shares |
Percentages use 2.19M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data